Evidence map›Paper›PMID 27087592›Full record

ArticleScientific reports2016

Establishment and characterization of HROC69 - a Crohn´s related colonic carcinoma cell line and its matched patient-derived xenograft.

Florian Kuehn, Christina S Mullins, Mathias Krohn, Christine Harnack, Robert Ramer, Oliver H Krämer, Ernst Klar, Maja Huehns, Michael Linnebacher

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. NSG mice as hosts for oncological precision medicine.Laboratory investigation; a journal of technical methods and pathology · 2020
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Florian KuehnUniversity Medicine Rostock, Department of General-, Thoracic-, Vascular- and Transplantation Surgery, Rostock, Germany.
Christina S MullinsUniversity Medicine Rostock, Department of General Surgery, Molecular Oncology and Immunotherapy, Rostock, Germany.
Mathias KrohnUniversity Medicine Rostock, Department of General Surgery, Molecular Oncology and Immunotherapy, Rostock, Germany.
Christine HarnackUniversity Medicine Rostock, Department of General-, Thoracic-, Vascular- and Transplantation Surgery, Rostock, Germany.
Robert RamerUniversity Medicine Rostock, Institute of Toxicology and Pharmacology, Rostock, Germany.
Oliver H KrämerUniversity Medical Center Mainz, Department of Toxicology, Mainz, Germany.
Ernst KlarUniversity Medicine Rostock, Department of General-, Thoracic-, Vascular- and Transplantation Surgery, Rostock, Germany.
Maja HuehnsUniversity Medicine Rostock, Institute of Pathology, Rostock, Germany.
Michael LinnebacherUniversity Medicine Rostock, Department of General Surgery, Molecular Oncology and Immunotherapy, Rostock, Germany.
University of Rostock · DEUniversity Medical Center of the Johannes Gutenberg University Mainz · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colitis-associated colorectal cancer (CAC) seems to be a rather unique entity and differs in its genetic alterations, tumour formation capacities, and clinical features from sporadic colorectal carcinoma. Most descriptions about tumour biology of CAC refer to ulcerative colitis; data about Crohn´s colitis related carcinomas are scarce. The majority of patients with Crohn´s disease are under immunosuppression which generates a different environment for tumour growth. We first describe the clinical case of a fast growing CAC in a long-term immunosuppressed patient with Crohn´s disease and successful establishment and characterization of carcinoma cell lines along with their corresponding patient-derived xenograft. Subsequently, these tumor models were molecularly and functionally analysed. Beside numerous chromosomal alterations, mutations in TP53, APC, PTEN and SMAD3 were identified. The cell lines express numerous cancer testis antigens, surface molecules involved in immune evasion but low levels of HLA class I molecules. They show strong invasive but in comparison weak migratory activity. The present work is the first description of patient-derived in vitro and in vivo models for CAC from a Crohn´s disease patient. They might be valuable tools for analysis of genetic and epigenetic alterations, biomarker identification, functional testing, including response prediction, and the development of specific therapeutical strategies.

Indexed as

Adenomatous Polyposis Coli ProteinAnimalsBiomarkers, TumorCarcinomaCell Culture TechniquesCells, CulturedChromosome AberrationsColonic NeoplasmsCrohn DiseaseGenes, MHC Class IHCT116 CellsHeterograftsHumansMaleMiceMiddle AgedAdenomatous Polyposis Coli ProteinAPC protein, humanBiomarkers, TumorPTEN PhosphohydrolaseSmad3 ProteinSMAD3 protein, humanTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID27087592
PMCPMC4834534
OpenAlexW2340354219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.